{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:59:35Z","timestamp":1781103575431,"version":"3.54.1"},"reference-count":39,"publisher":"National Academy of Sciences","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Study was funded by the Center for Biologics Evaluation and Research of the US Food and Drug Administration.","award":["No grant reference number applicable"],"award-info":[{"award-number":["No grant reference number applicable"]}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:p>Hepatitis C virus (HCV) infection frequently progresses to chronicity rather than spontaneous clearance, resulting in severe liver diseases including cirrhosis and hepatocellular carcinoma. The molecular mechanisms governing infection outcomes remain poorly understood. We identified Peptide A, a highly conserved epitope (residues 442 to 451) within HCV glycoprotein E2, and demonstrated that differential antibody binding patterns to this region correlate with distinct infection outcomes. This immunogenic, nonneutralizing epitope localizes to a structurally exposed region that shares residue 442 as a boundary with the previously characterized Epitope II (residues 430 to 442) and is positioned adjacent to variable region 2 (VR2, residues 460 to 485). Antibodies requiring both F442 and F447 residues within Peptide A for binding emerged early following infection and demonstrated strong correlation with chronic HCV progression. In contrast, antibodies binding exclusively to F447 were associated with spontaneous viral clearance and consistently co-occurred with Epitope II antibodies during later phases of infection. By establishing the relationship between these distinct antibody binding patterns and divergent infection outcomes, our findings elucidate potential HCV immune evasion mechanisms and may facilitate the development of predictive tools for determining chronic versus clearance outcomes early in infection, as well as inform rational vaccine design strategies.<\/jats:p>","DOI":"10.1073\/pnas.2522340122","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:39:09Z","timestamp":1767375549000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":0,"title":["Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection"],"prefix":"10.1073","volume":"123","author":[{"given":"Yong","family":"He","sequence":"first","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Ruvindi","family":"DeSilva","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam Sang","family":"Kwok","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3691-8820","authenticated-orcid":false,"given":"Lu","family":"Deng","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-5174","authenticated-orcid":false,"given":"Maria Luisa","family":"Virata","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Yan","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Major","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-5056","authenticated-orcid":false,"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health","place":["Bethesda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-2614","authenticated-orcid":false,"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"e_1_3_4_1_2","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000927"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.30024"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.02.001"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16050803"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2583"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3098"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243876"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb5642"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn9884"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39659-z"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07783-5"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110859"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.05.002"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03913-5"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007710"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01917"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703039104"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00029-06"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305306110"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2104242118"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28705"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02066-17"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.10.012"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6225"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5464.339"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.036"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49454-w"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.12.003"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.001"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00994-12"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00758-24"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28108"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403519101"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04390.x"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.04.012"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902749106"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2522340122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:39:16Z","timestamp":1767375556000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/10.1073\/pnas.2522340122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"alternative-id":["10.1073\/pnas.2522340122"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2522340122","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2522340122"}}